Navigation Links
Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

NYON, Switzerland, September 16 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company's mucosal HIV-AIDS vaccine designed for triggering mucosal protection. The results significantly exceed the Industry standard of 60% to 70% effectiveness to be considered as a promising vaccine as well as of Mymetics' expectation which was considerable above this level. The Company will continue to do further tests to confirm these results and will present the all results at the Keystone Symposia. With the recent public announcements by major HIV opinion leaders and pharmaceutical companies of their disappointing results despite significant investments in non productive vaccine strategies, attention is now beginning to refocus on the mucosa approach. Mymetics, with a robust IP portfolio and having originally decided 5 years ago to develop an HIV vaccine utilising mucosal antibody protection as the first line of defence, anticipates a fundamental change in the direction of HIV/AIDS research towards the mucosa solution in the near future.

Mymetics' viral challenge was its second non-human primate study conducted by the Institute of Laboratory Animal Science & Chinese Academy of Medical Science (ILAS) in Beijing. ILAS, a globally recognized analytical facility, have and continue to be used by leading US scientists and major governmental entities for ongoing scientific testing. This study used macaques for evaluating Mymetics' latest HIV vaccine formulation and consisted of three differing methodologies of immunizing the macaques. The macaques were intra-vaginally challenged thirteen times with the chimeric SHIV. Female Chinese Macaca Mulata (macaques) were chosen as their infection by SHIV through the genital route closely resembles the observed human infection rate by HIV. The company expects to present the fully detailed results as well as the challenge protocols at the next major conference on HIV/AIDS at the Keystone Symposia in Colorado in March 2009.

Reaching completion of the toxicology studies on animals, the company expects to initiate Phase I Human Clinical trials process in November 2008.

"Considering the repeated failures in developing a sustainable AIDS vaccine as widely reported in the press, we are very excited with the outstanding preliminary results of our viral challenge using our latest generation mucosal AIDS vaccine and look forward to a lively discussion on these results at the Keystone Conference" said Christian J. F. Rochet, President and CEO of Mymetics Corporation. "Our Chief Scientific Officer, Dr. Sylvain Fleury will attend the AIDS vaccine conference in South Africa in October and discuss informally our SHIV/AIDS results with other participants. We expect to release the complete results as well as the independent verification of those results at the Keystone Symposia. According to the WHO, it is estimated that there are over 33 million people living with HIV with a further 2.5 million new infections in 2007 alone. There is clearly an urgent need within the global community for an effective prophylactic AIDS vaccine and our results leave hope that the development of such a vaccine is not an impossible task."

Since 2004 Mymetics has pursued and furthered a mucosa approach that focuses on preventing early HIV entry into the human organism during the first minutes or hours following exposure to the HIV virus. Its success is based on proprietary know how and key intellectual property in matters of antigen engineering and vaccine design that has enabled Mymetics to engineer an effective vaccine candidate in the fight against HIV/AIDS.

About Mymetics Corporation

Mymetics is a biotechnology company developing prophylactic vaccines that combine innovative antigen engineering, minimal human protein homologies and virosome technology licensed from Pevion Biotech Ltd. Mymetics' vaccine approach focuses on eliciting immune protection capable of interfering with late events of pathogen transmission, a generally accepted approach coupled, uniquely and most importantly, with early events of pathogen transmission, such as preventing virus entry across the mucosal tissues, the primary entry door of most pathogens. Virosomes are lipidic vesicles derived from influenza virus membrane that are non-replicative antigen carriers which possess intrinsic systemic and mucosal adjuvant properties. Virosomes are approved in 42 countries and have been used since 1994 for two vaccines in over 40 million doses with no significant side effects. The Company's disease focus presently includes malaria and the human immunodeficiency virus.

For further information regarding the Company and its mucosal approach, please visit

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking statements."Such forward-looking statements are sometimes identified by words such as "intends,""anticipates,""believes,""expects" and "hopes."The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.


Investor Relations:

Anthony Jessop

Phone USA: +1-303-800-6606


SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
4. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015  Roche ... wholly-owned UK subsidiary Proximagen Ltd., today announced a worldwide ... small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), ... treatment of inflammatory disease. The VAP-1 inhibitor is currently ... --> Under the terms of the ...
(Date:11/30/2015)... LOUIS , Dec. 1, 2015 Express Scripts ... Imprimis Pharmaceuticals (NASDAQ: IMMY ) to drive access to ... for the treatment of toxoplasmosis that has been recently priced ... others with weakened immune systems. --> ... of pyrimethamine and leucovorin (a form of folic acid) for $1 ...
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... With FCPX Overlay: Grit , users can apply a grit ... are truly endless, all with a click of a mouse. Each user has full ... depth of field and more, all within Final Cut Pro X. , With FCPX ...
(Date:12/1/2015)... ... December 01, 2015 , ... SonaCare ... 2015 HSJ Acute Sector Innovation Award on November 18th. This prestigious award recognizes ... and propose exciting enhancements to the medical landscape. , The UCLH team won ...
(Date:11/30/2015)... ... 30, 2015 , ... Olympic Gold Medalists and Celebrity Moms ... across various categories through traditional and social media marketing campaigns and other branding ... Gold Medal Moms who can connect with today’s most important consumer: mothers. In ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
(Date:11/30/2015)... Los Angeles, California (PRWEB) , ... November 30, ... ... in all the programs of the19th Bi-National Convention of the Federation of Philippine ... Resort and Casino in Las Vegas, Nevada. , 1Heart Caregiver Services, as ...
Breaking Medicine News(10 mins):